Catalyst
Slingshot members are tracking this event:
CFDA has issued the Good Manufacturing Practices (GMP) certificate to Sinovac for the Company's Enterovirus 71 (EV71) vaccine. Market launch of the vaccine expected prior to the end of the second quarter of 2016
- Source Link:
- http://www.sinovac.com/?optionid=754&auto_id=804
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| SVA |
|
|
||||
Additional Information
This marks the completion of the final step of approval prior to commercial production. The company has begun commercial production of the EV71 vaccine and expects to deliver the vaccine to the market prior to the end of the second quarter of 2016 after the lot release testing is completed. The designed annual production capacity is 20 million doses.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 23, 2016
Occurred Source:
http://www.sinovac.com/?optionid=754&auto_id=825
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Cfda, Good Manufacturing Practices, Gmp, Enterovirus 71, Ev71, Vaccine, Approval
